Pantoprazole can affect this through 2 different nutrient pathways: Magnesium, Calcium. This medication is commonly used for Stomach Acid.
Each nutrient below contributes to this impact through a different mechanism.
Low or depleted magnesium levels are associated with a higher risk of osteoporosis and fractures, with studies linking magnesium deficiency to a 25–35% increased risk of hip, wrist, and spine fractures in some populations. Magnesium deficiency impairs bone mineralization and vitamin D activation, compounding skeletal weakness by disrupting osteoblast function and calcium balance. This is particularly concerning for older adults or those with additional risk factors, where monitoring magnesium status and considering supplementation may help mitigate bone loss.
Front Pharmacol. 2025 May 12;16:1592048. Rude RK, Singer FR, Gruber HE. Skeletal and hormonal effects of magnesium deficiency. J Am Coll Nutr. 2009 Apr;28(2):131-41. Liu L, Luo P, Wen P, Xu P. The role of magnesium in the pathogenesis of osteoporosis. Front Endocrinol (Lausanne). 2024 Jun 6;15:1406248. Li S, Chang W, Wu G, Wang K, Sun X, Sun H, Zhou J. Association between magnesium deficiency scores and hip bone health in adults: a population-based study. Magnes Res. 2025 Dec 1;38(3):81-94. Belluci MM, de Molon RS, Rossa C Jr, Tetradis S, Giro G, Cerri PS, Marcantonio E Jr, Orrico SRP. Severe magnesium deficiency compromises systemic bone mineral density and aggravates inflammatory bone resorption. J Nutr Biochem. 2020 Mar;77:108301.
In adults, chronically low calcium intake can quietly erode skeletal integrity, contributing to osteopenia, osteoporosis, and a higher risk of low‑trauma fractures over time. In children, inadequate calcium (often alongside vitamin D deficiency) impairs normal mineralization of the growing skeleton, leading to rickets with bone pain, deformities, and delayed growth, while in adults the same process manifests as osteomalacia with diffuse bone pain and muscle weakness rather than early fractures. The encouraging reality is that optimizing daily calcium intake, paired with sufficient vitamin D, protein, and weight‑bearing activity, has been shown to improve bone mineral density and meaningfully reduce fracture risk in at‑risk populations.
Bischoff-Ferrari HA, Rees JR, Grau MV, Barry E, Gui J, Baron JA. Effect of calcium supplementation on fracture risk: a double-blind randomized controlled trial. Am J Clin Nutr. 2008 Jun;87(6):1945-51. Cong B, Zhang H. The effects of combined calcium and vitamin D supplementation on bone mineral density and fracture risk in postmenopausal women with osteoporosis: a systematic review and meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2025 Oct 8;26(1):928. Heaney RP. Lifelong calcium intake and prevention of bone fragility in the aged. Calcif Tissue Int. 1991;49 Suppl:S42-5. Arnaud, C. D., Sanchez, S. D. The Role of Calcium in Osteoporosis. September 6, 2013. NASA. Lyndon B. Johnson Space Center, Spacelab Life Sciences 1: Reprints of Background Life Sciences Publications. Cairoli E, Aresta C, Giovanelli L, Eller-Vainicher C, Migliaccio S, Giannini S, Giusti A, Marcocci C, Gonnelli S, Isaia GC, Rossini M, Chiodini I, Di Stefano M; Italian Society for Osteoporosis, Mineral Metabolism, Skeletal Diseases (SIOMMMS). Dietary calcium intake in a cohort of individuals evaluated for low bone mineral density: a multicenter Italian study. Aging Clin Exp Res. 2021 Dec;33(12):3223-3235. Uday S, Högler W. Nutritional Rickets and Osteomalacia in the Twenty-first Century: Revised Concepts, Public Health, and Prevention Strategies. Curr Osteoporos Rep. 2017 Aug;15(4):293-302.
Some side effects may be linked to nutrient depletion caused by this medication.
Studies find that proton pump inhibitors (PPIs) may increase your risk of magnesium deficiency. A large study involving over 100,000 participants found a significant association between PPI use and lower magnesium levels (hypomagnesemia). PPIs work by reducing stomach acid production, which can also play a role in magnesium absorption. Individuals taking PPIs, particularly long-term use, should consider magnesium supplementation to help protect against deficiency.
Long-term use of PPIs might raise the risk of calcium deficiency and weaken bones. A potential mechanism for this is chronic hypergastrinemia, a condition where the stomach produces excess gastrin due to PPI use. This can lead to parathyroid hyperplasia, where the parathyroid glands overproduce a hormone that pulls calcium from bones. Additionally, PPIs significantly reduce stomach acid production, which can hinder calcium absorption from food in the intestines. Individuals taking PPIs, especially individuals at higher risk of bone issues or those on long-term PPI therapy, should consider calcium supplementation to help protect against deficiency.
There is evidence that proton pump inhibitors (PPIs) might decrease vitamin C levels in the body. A study showed that even a short course of omeprazole, a common PPI, reduced vitamin C levels in healthy volunteers, regardless of their dietary intake. This suggests that PPIs may reduce the bioavailability of vitamin C, meaning the body has a harder time absorbing and using it. Vitamin C plays a crucial role in immune function and antioxidant defenses and therefore individuals using PPI therapy should consider supplementation with vitamin C to protect against a deficiency.